$0.44-0.03 (-6.22%)
Milestone Scientific Inc., a biomedical technology company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical and dental use in the United States, China, and internationally.
Milestone Scientific Inc. in the Healthcare sector is trading at $0.44 with a market capitalization of $39M. Wall Street consensus targets $1.25 (2 analysts), implying a +184.1% move over the next 12 months. The stock is currently 31% below its 52-week high of $0.64, remaining 29.4% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.16Mβ | $2.06Mβ | $2.36Mβ | $2.32Mβ | $2.23M |
| Gross Profit | $1.56Mβ | $1.50Mβ | $1.64Mβ | $1.62Mβ | $1.65M |
| Operating Income | -$828,083β | -$1.08Mβ | -$1.13Mβ | -$1.48Mβ | -$2.00M |
| Net Income | -$839,853β | -$1.09Mβ | -$1.15Mβ | -$1.48Mβ | -$1.99M |
Milestone Scientific Inc., a biomedical technology company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical and dental use in the United States, China, and internationally. It ...
Milestone Scientific Inc (MLSS) posts strong Q2 with medical revenue up 231%, while reaffirming full-year guidance despite tariff pressures and a projected Q3 slowdown.

Moby summary of Milestone Scientific Inc.'s Q2 2026 earnings call
Milestone Scientific Inc (MLSS) narrows losses and doubles CompuFlow revenue despite geopolitical hurdles impacting shipments.
Moby summary of Milestone Scientific Inc.'s Q1 2026 earnings call
Milestone Scientific Inc (MLSS) reports a significant reduction in operating loss and outlines ambitious growth plans for 2026, despite facing ongoing financial challenges.